The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 14, 2025

Filed:

Dec. 12, 2022
Applicant:

Duynie Holding B.v., Alphen aan den Rijn, NL;

Inventors:

Allan Otto Fog Lihme, Farum, DK;

Marie Bendix Hansen, Frederiksberg, DK;

Bodil Ingrid Kjaer Lindved, Espergaerde, DK;

Assignee:

DUYNIE HOLDING B.V., Alphen aan den Rijn, NL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 1/30 (2005.12); A23J 1/00 (2005.12); A23K 10/35 (2015.12); A23L 2/02 (2005.12); A23L 2/70 (2005.12); A23L 5/20 (2015.12); A23L 19/12 (2015.12); B01D 61/14 (2005.12); C07K 1/32 (2005.12); C07K 14/415 (2005.12);
U.S. Cl.
CPC ...
A23J 1/006 (2012.12); A23K 10/35 (2016.04); A23L 2/02 (2012.12); A23L 2/70 (2012.12); A23L 5/20 (2016.07); A23L 5/276 (2016.07); A23L 19/12 (2016.07); B01D 61/145 (2012.12); C07K 1/30 (2012.12); C07K 1/32 (2012.12); C07K 14/415 (2012.12); A23V 2002/00 (2012.12); B01D 2311/12 (2012.12); B01D 2311/2642 (2012.12);
Abstract

The present invention in its broadest aspect relates to a method for reducing glycoalkaloid content and turbidity of an aqueous phase comprising compounds selected from two or more of PA, PI, PPO, LipO, pectin, lipid, glycoalkaloid and phenolic compounds of which at least one compound is selected from PA, PT, LipO and PPO; a) providing an aqueous phase comprising compounds selected from two or more of PA, PI, PPO, LipO, pectin, lipid, glycoalkaloid and phenolic compounds of which at least one compound is selected from PA, PT, LipO and PPO; and b) performing one or more steps to reduce the concentration of solanine in the dry matter of the aqueous phase with at least 15 percent, such as at least 20%, such as at least 25% and to achieve an optical density at 620 nm of the remaining aqueous phase of less than 0.7; such as less than 0.5; such as less than 0.3; such as less than 0.2; such as less than 0.1; and thereby obtaining an aqueous phase having reduced glycoalkaloid content and turbidity compared to an untreated aqueous phase.


Find Patent Forward Citations

Loading…